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Abstract
Purpose Enhancer of zeste homolog 2 (EZH2) is associated with epigenetic gene silencing and aggressiveness in many 
tumor types. However, the prognostic impact of high EZH2 expression is controversially discussed for colorectal cancer. For 
this reason, we immunohistochemically analyzed EZH2 expression in 105 specimens from colon cancer patients separately 
for tumor center and invasion front.
Methods All sections from tissue microarrays were evaluated manually and digitally using Definiens Tissue Studio soft-
ware (TSS). To mirror-image the EZH2 status at the tumor invasion front, we treated HCT116 colon cancer cells with the 
EZH2 inhibitor 3-Deazaneplanocin A (DZNep) and studied the growth of in ovo xenografts in the chorioallantoic membrane 
(CAM) assay.
Results We showed a significant decrease in EZH2 expression and the repressive H3K27me3 code at the tumor invasion 
front as supported by the TSS-constructed heatmaps. Loss of EZH2 at tumor invasion front, but not in tumor center was cor-
related with unfavorable prognosis and more advanced tumor stages. The observed cell cycle arrest in vitro and in vivo was 
associated with higher tumor aggressiveness. Xenografts formed by DZNep-treated HCT116 cells showed loosely packed 
tumor masses, infiltrative growth into the CAM, and high vessel density.
Conclusion The differences in EZH2 expression between tumor center and invasion front as well as different scoring and 
cutoff values can most likely explain controversial literature data concerning the prognostic value of EZH2. Epigenetic 
therapies using EZH2 inhibitors have to be carefully evaluated for each specific tumor type, since alterations in cell differ-
entiation might lead to unfavorable results.
Keywords EZH2 · EZH2 inhibition · Colorectal cancer · Tumor invasion front · Worse prognosis · CAM assay
Introduction
As the catalytic subunit of the polycomb repressive com-
plex (PRC2), histone methyltransferase EZH2, preferentially 
methylates lysine 27 on histone 3 (H3K27) and is associ-
ated with epigenetic gene silencing (Simon and Lange 2008; 
Kuzmichev et al. 2002; Margueron and Reinberg 2011). 
Besides its functional role for cell cycle regulation, EZH2 is 
also involved in metastasis by modulating tumor angiogen-
esis and the epithelial-to-mesenchymal transition, a process 
by which disseminating tumor cells acquire mesenchymal 
characteristics to migrate through the extracellular matrix 
(Simon and Lange 2008; Kim and Roberts 2016; Crea et al. 
2012). In different studies, overexpression of EZH2 has been 
identified as a biomarker of aggressive and highly proliferat-
ing tumors and is, hence, being associated with worse patient 
outcome, e.g., in endometrial, prostate, and breast cancer 
as well as melanoma (Bachmann et al. 2006). In colorec-
tal cancer (CRC), EZH2 expression could also be linked 
to cancer stem cell potential (Chen et al. 2016). Fussbroich 
et al. investigated the expression of EZH2 in colon cancer 
and adenomas immunohistochemically and reported a sig-
nificant increase in EZH2 expression in CRC, especially in 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0043 2-019-02977 -1) contains 
supplementary material, which is available to authorized users.
 * Regine Schneider-Stock 
 regine.schneider-stock@uk-erlangen.de
Extended author information available on the last page of the article
2228 Journal of Cancer Research and Clinical Oncology (2019) 145:2227–2240
1 3
less differentiated carcinomas (Fussbroich et al. 2011). Even 
though there is a general agreement about an increase in 
EZH2 expression in CRC compared to normal tissue, its 
prognostic value is controversially discussed (Benard et al. 
2014; Fluge et al. 2009; Liu et al. 2015; He et al. 2014). 
While some studies report that CRC patients having a high 
expression of EZH2 show a lower overall disease-free sur-
vival (DFS) (Liu et al. 2015; He et al. 2014; Mimori et al. 
2005), other reports describe that a high expression of EZH2 
in CRC patients is correlated with an improved relapse-free 
survival (Benard et al. 2014; Fluge et al. 2009; Takawa et al. 
2011). In a very recent report by Yamamoto et al., a signifi-
cant association between low EZH2 expression and shorter 
progression-free survival in 64 CRC patients was shown 
(Yamamoto et al. 2017). Interestingly, there is a stronger 
agreement concerning the significance of the EZH2-depend-
ent H3K27me3 code for cancer prognosis. In most studies, 
hypomethylated H3K27 was shown to be correlated with 
tumor aggressiveness in breast, ovarian, and pancreatic can-
cer as well as in colon carcinoma (Tamagawa et al. 2013; 
Wei et al. 2008). Hence, there might be cancer-related EZH2 
functions that are independent from H3K27 methylation. 
With respect to the analysis of EZH2 expression in CRC, 
the use of various scoring systems, different cutoff values, 
or mixed patient cohorts of colon and rectal tumors make it 
very difficult to compare the different studies and question 
the clinical application of EZH2 as a reliable biomarker. So 
far, there are also no studies considering a possible hetero-
geneity of EZH2 expression in the different tumor areas such 
as tumor center and invasion front.
In this study, we analyzed the expression of EZH2 in a 
cohort of 105 colon cancer patients with a median follow-up 
of 99.7 months. In particular, we were interested in the role 
of EZH2 in certain tumor areas. Thus, we focused on the 
invasion front, where cancer cells disseminate and migrate 
into the surrounding tissue. We propose a possible expla-
nation for the strongly opposing data in the literature in 
terms of EZH2 expression levels and their prognostic value 
in CRC. Moreover, for the first time we suggest a possi-
ble link between cell cycle stop and higher aggressiveness 
when EZH2 is inhibited, a phenomenon that is well known 
for the tumor invasion front. Our semi-automated software 
workflow can be applied for an objective and time-efficient 
analysis of immunohistochemical nuclear staining signals.
Materials and methods
Patient and tissue selection
We retrospectively analyzed a tumor group of 268 cases with 
primary adenocarcinoma of the colon that has not received 
neoadjuvant therapy and has undergone surgical resection at 
the University Hospital Erlangen (FAU Erlangen-Nürnberg) 
between 2005 and 2009. Clinical information and follow-up 
data were collected prospectively by the Erlangen Regis-
try for Colorectal Carcinoma (ERCRC). This retrospective 
study is covered by ethic votes of the FAU (24.01.2005, 
18.01.2012). For clinical correlation of the data, we defined 
that the complete clinical data set and at least two tissue 
samples per patient both have to be available, at the invasion 
front and in the center, to avoid bias caused by tumor het-
erogeneity. This led to a final number of 105 patients. This 
cohort included 54 (51.4%) men and 51 (48.6%) women. 
Median of the patient’s age was 66 years (range 39–89). 56 
(53.3%) of the patients had an UICC stage of I or II and 49 
(46.7%) were staged as III or IV. While 80 (76.2%) patients 
did not carry distant metastases and 25 (23.8%) patients had 
M1 tumors, 45 (42.9%) patients showed lymph node metas-
tases. The median follow-up time was 99.7 months (range 
1–136 months). The 5-year cancer-related survival rate was 
75.4%; at the time of analysis, 55 of the 105 patients (52.4%) 
had died, 33 (31.4%) died of disease (Table 1). Tumor bud-
ding has been scored according to the guidelines of the Inter-
national Tumor Budding Consensus Conference 2016 (Lugli 
et al. 2017). Examples are given in Online Resource 1.
Specimens were formalin fixed and paraffin embedded 
(FFPE). Histopathological review of all diagnostic cases 
was performed by three pathologists (TTR, CG, AH). The 
tumors were staged according to the eighth ed. of the UICC 
TNM classification.
TMA construction
TMA has been constructed as previously described (Nolte 
et al. 2017). For this, three representative punches with a 
diameter of 0.6 mm were taken out of both the tumor center 
and the invasion front for each patient using a TMA Grand 
Master (3DHISTECH, Budapest, Hungary; Online Resource 
2) and then cut to a thickness of 3 µm.
Cell lines
The human colorectal tumor cell line HCT116 (CCL-247, 
ATCC) was kept in RPMI medium supplemented with 10% 
FBS and 1% penicillin/streptomycin. Cells were cultured in 
a humidified incubator at 37 °C with 5%  CO2.
The cell line was authenticated using Multiplex Cell 
Authentication by Multiplexion (Heidelberg, Germany). 
Mycoplasma-free status has been verified.
Crystal violet assay
HCT116 cells were seeded in 96-well plates (10,000 cells/
well) and incubated for 24 h. Cells were then treated with 
a concentration range of 3-Deazaneplanocin A (DZNep, 
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Table 1  Patient characteristics 
and association with 
immunohistochemical EZH2 
expression





IF ≤ 30 (%)
EZH2 score
IF > 30 (%)
p value
Gender
 Male 54 (51.4) 30 (55.6) 24 (44.4) ns
 Female 51 (48.6) 24 (47.1) 27 (52.9)
Patient age
 Median (min, max) 66 (39–89) – – nsa
Histological subtype
 Adenocarcinoma (NOS) 88 (83.8) 44 (50.0) 44 (50.0)
 Mucinous 13 (12.4) 7 (53.8) 6 (46.2)
 Other 4 (3.8) 3 (75.0) 1 (25.0) ns
UICC
 I 20 (19.1) 7 (35) 13 (65)
 II 36 (34.3) 14 (38.9) 22 (61.1)
 III 24 (22.8) 13 (54.2) 11 (45.8)
 IV 25 (23.8) 20 (80) 5 (20) 0.005**
Grading
 1 5 (4.8) 1 (20.0) 4 (80.0)
 2 63 (60.0) 32 (50.8) 31 (49.2)
 3 37 (35.2) 21 (56.8) 16 (43.2) ns
pT
 pT1 6 (5.7) 2 (33.3) 4 (66.7)
 pT2 17 (16.2) 8 (47.1) 9 (52.9)
 pT3 60 (57.1) 29 (48.3) 31 (51.7)
 pT4 22 (21.0) 15 (68.2) 7 (31.8) ns
cM/pM classification
 M0 80 (76.2) 34 (42.5) 46 (57.5)
 M1 25 (23.8) 20 (80.0) 5 (20.0) 0.01*
pN classification
 pN0 60 (57.1) 24 (40.0) 36 (60.0)
 pN1–2 45 (42.9) 30 (66.7) 15 (33.3) 0.004**
Localization
 Cecum 17 (16.2) 8 (47.1) 9 (52.9)
 Ascending colon 26 (24.8) 14 (53.8) 12 (46.2)
 Transverse colon and flexures 15 (14.3) 7 (46.7) 8 (53.3)
 Descending colon 6 (5.7) 2 (33.3) 4 (66.7)
 Sigmoid colon 41 (39.0) 23 (56.1) 18 (43.9) ns
Localizationb
 Proximal 54 (51.4) 27 (50) 27 (50)
 Distal 51 (48.6) 27 (52.9) 24 (47.1) ns
Perineural invasion
 Yes 7 (6.7) 4 (57.1) 3 (42.9)
 No 96 (91.4) 49 (51) 47 (49)
 Unknown 2 (1.9) 1 (50) 1 (50) ns
Lymphatic invasion
 Yes 28 (26.7) 16 (57.1) 12 (42.9)
 No 77 (73.3) 38 (49.4) 39 (50.6) ns
MMRP expression
 Lossc 25 (23.8) 13 (52) 12 (48)
 Intact 80 (76.5) 41 (51.2) 39 (48.8) ns
Tumor budding
 Low 56 (53.3) 24 (42.9) 32 (57.1)
 Intermediate 28 (26.7) 18 (64.3) 10 (35.7)
 High 21 (20) 12 (57.1) 9 (42.9) ns
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250 nM to 100 µM) for another 48 h. Afterward, cells were 
washed with 200 µL of PBS and stained with 50 µL of a 
Crystal Violet staining solution (0.5% Crystal Violet; 20% 
MeOH in  ddH2O) for 15 min at room temperature. Finally, 
cells were washed three times with 200 µL of  ddH2O and 
the plates were air dried before dissolving the Crystal Violet 
in 10% acetic acid (200 µL). Absorption was measured at 
595 nm using a Victor™ X3 2030 Multilabel Plate Reader 
(PerkinElmer). Percentages of viable cells were calculated 
compared to respective DMSO controls (100% of viable 
cells).
Western blot analysis
HCT116 cells (1.5 × 106 cells) were seeded into 10-cm 
cell culture dishes and incubated for 24  h. Then cells 
were treated with DZNep (5 µM) for 1, 3, 6, 24, and 48 h. 
Untreated HCT116 cells were served as control. After the 
indicated incubation periods, cells were harvested, washed 
in PBS, and proteins were extracted by lysis with Urea 
Lysis Buffer. Protein concentration was measured using 
the Bio-Rad DC™ Protein Assay (BioRad). Equal amounts 
of lysates were applied to SDS-PAGE and proteins were 
then transferred to a nitrocellulose membrane (Amersham 
Protran Premium 0.2 NC, GE Healthcare Life Sciences) 
prior to probing with antibodies. Antibodies were applied 
as follows: anti-EZH2 (1:10,000, EZH2 (D2C9) XP, mono-
clonal rabbit, Cell Signaling), anti-H3K27me3 (1:10,000, 
Tri-Methyl-Histone H3 (Lys27) (C36B11, monoclonal rab-
bit, Cell Signaling), anti-GAPDH-HRP as loading control 
(1:50,000, clone 6C5, monoclonal mouse, Abnova), and 
secondary HRP-conjugated antibody (1:10000, Goat anti-
Rabbit IgG (H + L, Thermo Scientific). Signal of protein 
bands was detected using chemiluminescent HRP substrate 
(Immobilon™ Western Chemiluminescent HRP substrate, 
Millipore) according to the manufacturer’s instructions and 
the GeneGnome detection system (Syngene).
CAM assay
To study the in vivo growth pattern of tumor cells with 
decreased EZH2 activity, we treated HCT116 cells 
(1.5 × 106) with the EZH2 inhibitor DZNep (5 µM,  IC30 
range as determined by Crystal Violet and applied in the 
literature) for 48 h (Sha et al. 2015). The in ovo CAM assay 
has been performed as described previously (Ribatti 2017; 
Muenzner et al. 2018). Specific pathogen-free (SPF) eggs 
were bred in an incubator at 37 °C and in a relative humidity 
of 70–80%. On day 8 of chicken embryo development, a 
window (Ø ~ 1–1.5 cm) was cut into the more rounded pole 
of the eggs and the egg shell membrane was removed. The 
windows were sealed with silk tape (Durapore™, 3 M) and 
the eggs were incubated for another day. Then control cells 
(untreated, n = 10) and DZNep-treated (n = 9) HCT116 cells 
(1 × 106) were embedded in Matrigel  (Corning®  Matrigel® 
Basement Membrane Matrix, 356237; 1:1 mixture with 
medium; total volume 40 µL per pellet) and the resulting 
pellets were placed on the CAM of the developing embryos 
(day 9 of incubation). Microtumors with their surround-
ing CAM were harvested 5 days after engraftment on the 
CAM, fixed in 4% phosphate buffered formalin for 24 h, 
and embedded in paraffin. The tumor volume was calcu-
lated using a formula for ellipse calculation prior to fixa-
tion: Tumor volume = pellet length*width*height* × 0.52.
Cell cycle analysis
To verify the known G1-arresting effects of DZNep, 
1.25 × 106 cells were seeded into 6-cm cell culture dishes and 
incubated for 24 h (Sha et al. 2015). Then cells were treated 
with 5 µM DZNep or a respective amount of DMSO (solvent 
control) for an additional 24 h. Finally, cells were harvested 
by trypsinization, washed with PBS, fixed in 70% ethanol 
overnight (4 °C), rehydrated and stained with propidium 
iodide (30 min at room temperature in the dark; propidium 
iodide staining buffer: 224 µM propidium iodide, 3.875 mM 
sodium citrate, 0.1% Triton X-100, and 0.5 mg/mL RNase A 
in PBS,). Cell cycle analysis was performed using a FACS 
Calibur flow cytometer (BD). Per sample 10,000 single cells 
were analyzed and the different cell populations (sub-G1 
fraction, G1-, S- and G2/M-phase) were determined using 
the FlowJo software (FlowJo7.6.5).
Immunohistochemistry of CAM tumors
Serial sections (2 µm) were cut from the paraffin blocks and 
mounted on pre-coated slides for immunohistochemical 
analysis of the CAM tumors.
All FFPE whole (CAM) tissue sections and TMAs were 
deparaffinized with xylene and rehydrated with graded etha-
nol. The antigen retrieval was performed by 1 min steam 
cooking in TRS buffer pH 6. Slides were incubated at 4 °C 
overnight with primary monoclonal antibody EZH2 1:500 
(Rabbit, D2C9, Cell Signaling) or anti-H3K27me3 1:300 
(Rabbit, C36B11, Cell Signaling). Antibody binding was 
visualized using the Polymer-Kit (AP, Zytomed). Adjacent 
a Pearson correlation coefficient = − 0.068 (p = 0.489)
b Proximal: cecum, ascending, right flexure, transverse; distal: left flexure, descending, sigmoid
c Loss of MMRP expression in at least one of the four markers hMLH1, hMLH2, hMSH6, and PMS2
Table 1  (continued)
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slides were stained with hematoxylin and eosin for histomor-
phological analyses. Immunohistochemical scoring was per-
formed in a semi-quantitative way by two researchers (AVR, 
JB). Intensity was quantified by nuclear reaction in a range 
from 1 to 3 (Online Resource 3). Area was quantified by per-
centage of positive cells in 5% steps. EZH2 and H3K27me3 
immunoscores were generated by multiplying intensity (0–3) 
with the respective percentage of positive cells (0–100%). 
The manual analysis only considered the groups of highest 
intensity for each punch. The EZH2 score was then used for 
correlation with clinical data. Samples were only included, 
if at least two of three punches were analyzable.
The tumor cell area of the CAM microtumors was meas-
ured using the Case Viewer software (3D HISTECH ltd. 
Version 2.0) and scans of HE-stained slides were performed 
using a digital slides scanner (Scanner FLASH II using CIS 
VCC FC60FR19CL Camera (0.19 microns/pixel in 40 ×), 
3D-Histech, Budapest, Hungary). The tumor cell area was 
then calculated as a percentage of the total microtumor area 
including residual Matrigel but excluding the CAM tissue. 
For the quantification of blood vessels, we used HE-stained 
slides and included only blood vessels containing nucle-
ated chicken erythrocytes. Besides counting the amount of 
blood vessels of the microtumors (intra- and peri-tumoral), 
the relative vessel density was determined by dividing the 
area of blood vessels by the total microtumor area including 
residual Matrigel.
Immunohistochemistry of mismatch repair proteins
Immunohistochemistry was performed on 2-μm-thick sec-
tions of FFPE tumor blocks on a Ventana BenchMark Ultra 
automated instrument (Ventana Medical Systems, Inc., 
Tucson, AZ, USA) according to routine standards of our 
institute and manufacturer’s recommendations. The follow-
ing mouse monoclonal antibodies have been used: MLH1 
(ES05, 1:50, DAKO), MSH2 (clone 760-4265, ready-to-
use, Ventana), MSH6 (clone 44/MSH6, 1:100, BD), PMS2 
(clone EP51, 1:40, DAKO).
Heat-induced epitope retrieval was performed using CC1 
at 95 °C for 36 min for tissue preparation for each staining. 
Then incubation of the pre-treated tissue sections was fol-
lowed for 20 min at room temperature for the MLH1 anti-
body, whereas for the MSH2 antibody incubation at 37 °C 
for 16 min and for the MSH6 and PMS2 antibody 30 min 
at room temperature was performed. Binding of the anti-
bodies to the antigen was visualized using the ultraView 
Universal DAB Detection Kit, and subsequently, sections 
were counterstained with Hematoxylin and Bluing Reagent 
(Ventana). Assessment of MLH1, MSH6, MSH2, and PMS2 
was performed by two independent observers (CG, AH) who 
were blinded to the clinical data. For all four IHC stainings, 
a nuclear staining of > 10% of the tumor cells was considered 
as a positive expression. The absence of staining at > 90% of 
all tumor cells was considered as loss of MMRP but posi-
tive internal control was checked (e.g., endothelial cells or 
cells of the connective tissue). Analysis has been performed 
according to the German S3 guidelines for colon cancer in 
its actual version (German S3-Guidelines Colorectal Cancer 
2019).
Computer‑assisted digital and manual analysis
Stained slides were scanned using a Pannoramic MIDI 
(Camera type: CIS_VCC_F52U25CL, Objective name: 
Plan-Apochromat, Objective magnification: 40 ×, Cam-
era adapter magnification: 1 ×) (3DHISTECH, Budapest, 
Hungary). Pannoramic Viewer software Version 1.15.4 
(3DHISTECH, Budapest, Hungary) was used to view and 
annotate all TMAs and whole slides. We applied Definiens 
Tissue Studio Software Version 4.0 (TSS; Definiens AG, 
Munich, Germany) to obtain a semi-automated score for 
all cores on the center TMAs and correlated it to the same 
score, which was acquired by manual analysis. This TSS 
score was generated by multiplying intensity (0–3) with per-
centage of the positive cells (0–100%) resulting in values of 
0–300. In contrast to manual analysis, the TSS analyzed all 
staining intensities.
For the correlation of EZH2/H3K27me3 code scores 
derived by either the TSS software or the pathologist, we 
used all punches that were available for both stainings, inde-
pendent of center and invasion front (268 patients × maxi-
mum 6 punches per case = 1608). Not all punches were 
analyzable by the pathologists or the TSS due to artifacts 
or a very low number of cells. Only punches were included 
when both stainings for EZH2 and H3K27me3 were avail-
able. This led to the final number of 766 different punches 
for statistical evaluation of correlation.
By manual training of the software and control of the 
regions of interest (ROIs, e.g., stroma or epithelial cells) 
that the software recognizes, we guaranteed a minimum of 
mistakes by the “Composer: Training” tool, which annotates 
the ROIs. The workflow contained marking ROIs by hand 
in as many examples and as accurate as possible. After this 
extensive training, the software was able to mark ROIs on its 
own. Nevertheless, we randomly chose software annotated 
slides to review whether the training was performed properly 
and corrected annotations if necessary. The same procedure 
was used for every step, in which the software had to select 
and classify different tissues or intensities. Different nuclear 
intensities were taught to the software using representative 
examples of those intensities (Fig. 1), and then adjusting the 
thresholds with TSS. Nuclei underneath 20% of the typi-
cal nucleus size measured by the software were excluded to 
reduce the impact of artifacts.
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With the experience acquired during the semi-automated 
TMA analysis, we edited eight whole slides in an identical 
manner to establish heatmaps using the “Heatmap” feature, 
which is accessible via TSS, to clearly display our results in 
the tumor center and at the invasion front.
Statistical analysis
The correlations between coded EZH2 score (cutoff 
score = 30 as median) and clinicopathological variables 
(sex, localization, subtype, pT-, pN-, and M-category, UICC 
stage, grading) were calculated using the χ2 test or Fisher’s 
exact test in cross tables. Unpaired t test was used to corre-
late EZH2 immunoscore and clinicopathological parameters. 
For direct comparison of the values at the invasion front and 
the tumor center, paired t tests (Wilcoxon) were applied. 
Spearman correlation was used to compare the EZH2 and 
H3K27me3 scores determined by the pathologists and the 
Definiens TSS. All tests were two sided. The Kaplan–Meier 
curves of cancer-related survival were compared using a 
log-rank test. Death from unrelated causes has been cen-
sored. Univariate Cox regression analysis was performed 
to evaluate the risk of dying of disease for EZH2 and clin-
icopathological parameters. All variables with p < 0.05 in 
univariate analysis were included into a multivariate model 
to identify independent prognostic factors. p values of < 0.05 
were considered to be statistically significant. The statisti-
cal analysis was performed using SPSS Version 21 (IBM, 
Armonk, New York).
Results
Selected clinical data of patients and EZH2 immunoscores 
are presented in Table 1 to give an overview of the 105 
patients investigated.
Fig. 1  Image analysis of Tissue Studio at different steps. Original 
images with EZH2 staining are shown left. Tissue recognition dem-
onstrates the marked ROIs (orange: cancer cells, blue: stroma, light 
yellow: white space). The same cores after usage of the Tissue Stu-
dio cellular analysis tool are shown right. Blue nuclei are negative for 
EZH2; yellow, orange, and red colors represent intensities 1, 2, and 3, 
respectively. Scale bar 600 µm
Fig. 2  Comparison of EZH2 
staining intensity in tumor 
center and at the invasion front. 
a EZH2 staining intensity 
decreases from tumor center to 
invasion front (× 4 magnifica-
tion) considering a whole slide 
(b) and three TMA cases (× 10 
magnification). Tumor center is 
shown on the left, invasion front 
on the right side. c, d Statistical 
analysis (line diagram, error bar 
diagram) clearly verifies a loss 
of EZH2 expression at the inva-
sion front (n = 105; p < 0.001). 
Scale bar 400 µm
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EZH2 and H3K27me3 stainings
Both stainings were majorly found in the nucleus of the 
tumor cells (Fig. 2a, b) with a significant decrease in EZH2 
expression at the tumor invasion front (p < 0.001, Fig. 2c, 
d). The EZH2 and the H3K27me3 stainings were almost 
homogeneous (Online Resource 2) demonstrating that the 
punches were representative of the respective whole tumor 
slices. Correspondingly, there was a significant decrease in 
the H3K27me3 code at the invasion front (p < 0.001). When 
evaluating the 766 punches for correlation between EZH2 
and H3K27me3 code, we did not find a significant correla-
tion between both markers.
Clinicopathological data and survival analysis
We could confirm that MMRP loss occurs more frequently 
in the proximal colon (proximal: 16/54 (29.6%) and distal: 
9/51 (17.6%). We identified low and intermediate tumor 
budding in 80% of cases whereas high tumor budding was 
found in 21 tumors (20%; Table 1).
Follow-up data were available for all 105 colon cancer 
patients. The cancer-related 5-year survival rate was 75.4% 
(95% CI 67.0–83.8). Males affected by colon cancer had 
a worse prognosis than females (Online Resource 4a). 
The Kaplan–Meier curve reflected the prognostic value of 
UICC stage (Online Resource 4b) with patients having a 
high UICC stage showing a worse cancer-related survival. 
 pT3 and  pT4 categories were significantly correlated with a 
worse prognosis (Online Resource 4c). The occurrence of 
lymph node metastases and distant metastases was signifi-
cantly associated with a worse prognosis for patients (Online 
Resource 4d, e). High tumor budding was significantly cor-
related with worse prognosis (Online Resource 4f). The 
stratification regarding the tumor grade (Online Resource 
4g), MMRP status, and proximal/distal localization did not 
reach significance (data not shown). Consistently, Univariate 
Cox analysis revealed a high prognostic value for M status, 
pN category, pT category, and tumor budding with signifi-
cant p values < 0.05 (Table 2). When including all param-
eters that were significant in the Univariate Cox analysis, 
distant metastasis and EZH2 difference were confirmed as 
independent prognostic factors (Table 2).
Our findings demonstrate that the sampling was accurate 
and our tumor group is representative for colon cancer.
EZH2 expression and clinical outcome
Even though EZH2 expression in the tumor center did not 
correlate with any of the clinical data, EZH2 expression at 
the tumor invasion front was significantly correlated with 
poor clinical outcome. In general, lower EZH2 expression 
could be linked to higher tumor aggressiveness (Table 2) 
as advanced tumors (UICC III and IV, or tumors with 
lymph node or distant metastases) showed lower EZH2 
expression (Fig. 3a–c). Indeed, 10 of 42 patients (23.8%) 
with an EZH2 immunoscore of < 30 died of disease, 
whereas only 3 of 42 patients (7.1%) with tumors highly 
expressing EZH2 died of disease. Low EZH2 expression 
was significantly correlated with an unfavorable progno-
sis (p = 0.023; Fig. 3d). In the Univariate Cox regression 
model, we found an approximately 0.4-fold risk of dying of 
disease for patients who had high EZH2 expressing tumors 
(Table 2; cut-off score at 30). Next, we estimated the dif-
ference between the corresponding EZH2 immunoscores 
in the center and at the invasive front (Δcenter–invasion 
front). Tumors that showed a loss of EZH2 at the inva-
sion front (i.e., a reduction of more than ten) had a worse 
prognosis (p = 0.038; Fig. 3e). In contrast, tumors that had 
an equal EZH2 expression in both the areas or even an 
increased EZH2 immunoscore at the invasion front had a 
Table 2  Prognostic significance (cancer-related survival) of clinico-
pathological parameters using the Cox’s regression model
*p < 0.05, ***p < 0.001
a EZH2 score (Δtumor center–tumor invasion front)
b Proximal versus distal
c Low/intermediate versus high
Parameter N Cancer-related survival





pT category 105 12.3 1.7–90.3 0.013*
pN category 105 5.5 2.5–11.8 < 0.001***
M category 105 18.8 8.4–42.1 < 0.001***
EZH2 score 30 105 0.4 0.2–0.9 0.027*
EZH2  differencea 105 2.1 1.0–4.2 0.042*
Tumor grading 105 1.3 0.7–2.7 0.403
Sex 105 0.5 0.2–1.0 0.064
Age (66 cutoff) 105 1.3 0.6–2.5 0.488
Localizationb 105 1.3 0.7–2.6 0.438
MMRP loss 105 1.0 0.4–2.2 0.948
Tumor  buddingc 105 2.5 1.2–5.3 0.016*
Multivariate analysis
pT category 105 4.2 0.5–33.3 0.173
pN category 105 2.1 0.9–5.2 0.091
M category 105 12.3 4.8–31.6 < 0.001***
EZH2 score 30 105 1.6 0.6–3.9 0.318
EZH2  differencea 105 2.8 1.3–6.2 0.012*
Tumor  buddingc 105 1.4 0.6–3.4 0.404
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more favorable prognosis. In the Univariate Cox regres-
sion model, a reduction in the EZH2 immunoscore of > 10 
was associated with a 2.1-fold increased risk of dying of 
disease (Table 2). The EZH2 Δcenter–invasion front score 
reached significance in the Multivariate Cox analysis sug-
gesting an independent prognostic value in CRC (Table 2).
Modeling EZH2 low expression tumors in CAM 
xenografts
We aimed to simulate the observed EZH2 loss at the inva-
sion front in human tumors by treating HCT116 colo-
rectal cancer cells with the EZH2 inhibitor DZNep and 
transplanted  106 of these cells onto the CAM of 9-day old 
chicken embryos.  IC30 range has been determined by Crys-
tal Violet assay for suitable treatment of HCT116 cells 
(Online Resource 5a). Western Blot analysis showed that 
EZH2 protein levels slightly decreased after DZNep treat-
ment (Fig. 4a). In ovo CAM, xenografts are exemplarily 
shown in Fig. 4b. In our study, we could observe that 
DZNep treatment also led to a slight reduction in EZH2 
levels in CAM tumors (n = 9) when compared to untreated 
HCT116 control (n = 10) CAM microtumors (Fig.  4c, 
EZH2 immunoscore). In general, DZNep CAM microtu-
mors were smaller (Fig. 4c, tumor volume) and exhibited 
a lower number of cells growing in clusters with large 
cell-free Matrigel areas, which would be expected due to 
the well-known stop of cell proliferation caused by DZNep 
treatment (Fig. 4c, Online Resource 4b) (Sha et al. 2015). 
Despite their cell cycle arrest, we observed that DZNep-
treated tumor cells showed a highly invasive growth into 
the CAM (Fig. 4d) and their tumors displayed a higher 
grade of vascularization. A significantly greater number 
of vessels as well as a higher vessel density per graft area 
(Fig. 4e) in DZNep-treated CAM tumors demonstrated a 
pronounced aggressive phenotype when EZH2 is lost. A 
reduction of EZH2 at the invasion front could be verified 
in both treated and untreated HCT116 CAM xenografts 
corroborating our clinical data (Fig. 4f.1). Additionally, a 
Fig. 3  Correlation of EZH2 
expression with clinicopatho-
logic features. a–c A loss 
of EZH2 immunoscore at 
the invasion front is highly 
correlated to UICC stages 
3 + 4, distant metastases, 
and lymph node metastases. 
Cloud diagrams show the 
median ± range. Kaplan–Meier 
plot demonstrates that lower 
EZH2 expression (d) and the 
difference between the corre-
sponding EZH2 immunoscores 
in the center and at the invasive 
front (Δcenter–invasion front) 
(e) correlate significantly with 
worse prognosis of patients
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very high heterogeneity regarding the intensity of EZH2 
and H3K27me3 code staining could be detected in the 
tumors formed by DZNep-treated HCT116 cells (Fig. 4f.2, 
g). The higher vessel density is exemplarily displayed by 
HE staining in Fig. 4d.1.
Tissue Studio software (TSS)
The analysis of the semi-automated software was com-
pared to the manual one using the above-mentioned scoring 
technique. Evaluating a total number of 766 punches, the 
interobserver correlation between the TSS and two experts 
(JB, AVR) was highly significant for EZH2 (rs = 0.289; 
p < 0.001) and H3K27me3 (rs = 0.796; p < 0.001).
To validate the TMA data for the tumor center, we 
selected eight whole tissue sections and compared the results 
of the manual evaluation of EZH2 immunostainings with 
the results obtained from core punches represented on the 
TMA. We were able to show a high concordance between 
immunostaining scores obtained from core punch and their 
corresponding whole tissue sections in seven out of eight 
cases. With the help of TSS, we constructed heatmaps that 
Fig. 4  Evaluation of in  vivo staining pattern using the CAM assay. 
a HCT116 cells were treated with 5 µM DZNep and time-dependent 
effects on the expression of EZH2 were analyzed by Western Blot. 
b Exemplary in ovo microtumor images. c EZH2 immunoscore as 
determined from CAM assay micro-xenografts of untreated (n = 10) 
and DZNep-treated (n = 9) HCT116 cells; tumor volume of CAM 
assay microtumors of untreated (n = 10) and DZNep-treated (n = 9) 
HCT116 cells; tumor cell area as obtained from analysis of HE stain-
ings of untreated (n = 10) and DZNep pre-treated (n = 9) HCT116 
microtumors. d Exemplary H&E stainings of CAM assay microtu-
mors of untreated and DZNep-treated HCT116 cells; IF invasion 
front; magnification × 20, scale bar 50  µm. d.1 Manually enlarged 
image of exemplary H&E staining, stars: chicken vessels with nucle-
ated erythrocytes. e Number of blood vessels as determined by count-
ing the number of blood vessels in the total area of untreated (n = 10) 
and DZNep-treated (n = 9) HCT116 microtumors; vessel density as 
calculated from area of blood vessels in the total area of microtu-
mors of untreated (n = 10) and DZNep-treated (n = 9) HCT116 cells. 
f Exemplary EZH2 stainings of CAM assay microtumors of untreated 
and DZNep-treated HCT116 cells; magnification × 20, scale bar 
50 µm. f.1, f.2 Manually enlarged images of exemplary EZH2 stain-
ings; triangles showing different EZH2 intensity; magnification 
× 40, scale bar 20  µm. g Exemplary H3K27me3 staining of CAM 
assay microtumors of DZNep-treated HCT116 cells, magnification 
× 20, scale bar 50  µm. g.1 Manually enlarged images of exemplary 
H3K27me3 staining with different staining intensity (triangle), mag-
nification × 40, scale bar 20 µm
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show the density of EZH2 and H3K27me3 positive cells 
by decoding it into different colors (Figs. 1, 5). Here, the 
software confirmed the results of the manual analysis dem-
onstrating a remarkable loss of EZH2 and the corresponding 
repressive H3K27me3 code expression at the tumor invasion 
front compared to the tumor center.
Discussion
EZH2, a component of the polycomb repressive complex 
2, is involved in stable transcriptional repression during 
embryogenesis and under pathological conditions such as 
cancer. It is an important epigenetic regulator for genes 
that are involved in differentiation, proliferation, and stem 
cell renewal (Kim and Roberts 2016). In cancer, it has been 
reported that EZH2 seems to play a dual role as either an 
oncogene or tumor suppressor; however, the molecular 
mechanisms behind this antagonistic duality are not well 
understood (Margueron and Reinberg 2011). For this reason, 
it is not surprising that reports about the prognostic signifi-
cance of EZH2 in cancer are highly divergent. EZH2 overex-
pression has been associated with aggressive tumor growth 
in breast cancer, in endometrial carcinomas, and melanoma 
as well as in prostate cancer (Bachmann et al. 2006). In these 
tumor entities, a high EZH2 expression has been linked to 
advanced disease and worse prognosis. In contrast, 2 recent 
meta-analyses concerning EZH2 expression in CRC tumors, 
one including 8 studies and more than 1059 CRC patients, 
while the other one comprised 10 studies with 1461 CRC 
patients, showed that EZH2 overexpression indicates a better 
prognosis in CRC and that EZH2 is not an indicator of poor 
prognosis, respectively (Vilorio-Marqués et al. 2017). With 
our study, we support the latter findings: there is no prognos-
tic potential for EZH2 in the center of colon tumors. Never-
theless, loss of EZH2 at the tumor invasion front seems to 
be correlated with a more aggressive phenotype of cancer 
cells in colon cancer patients. By carefully evaluating the 
opposing data in the literature about the prognostic value of 
EZH2 in colon cancer, we recognized marked differences in 
the study designs that may contribute to these controversies. 
First, most studies did not distinguish between patients with 
colon and rectal cancer (Benard et al. 2014; Mimori et al. 
2005; Takawa et al. 2011). Indeed, Fluge et al. found strong 
differences when analyzing colon and rectal tumors sepa-
rately and reported a significant correlation of low EZH2 
expression to relapse-free survival only in colon, but not 
in rectal cancer (Fluge et al. 2009). Thus, mixed groups of 
colon and rectal cancer can strongly influence the prognostic 
value of EZH2 expression. For this reason, we only analyzed 
colon tumors. Second, there are no studies considering a 
possible heterogeneity of EZH2 expression in the center and 
at the invasion front of a tumor. Interestingly, we found a 
significant decrease in EZH2 staining at the invasion front of 
colon tumors in our study. One would expect that genes that 
are upregulated by the low H3K27me3 code are different in 
normal cells and in cells at the tumor invasion front. In both 
areas, we see low EZH2/H3K27me3 code expression; nev-
ertheless the functional consequences have to be completely 
different from each other. Moreover, the lack of a significant 
correlation between EZH2 and its repressive code might lead 
to the conclusion that there are also H3K27me3 independent 
functions of EZH2.
In addition to the well-known general involvement of 
EZH2 in cell cycle regulation, which especially affects cells 
with high mitotic activity (Simon and Lange 2008), it was 
Fig. 5  Heatmap construction. a, b Two examples of whole H&E-
stained tissue slices with heatmap overlay showing the density of 
EZH2/H3K27me3 positive cells: low density areas are given in green, 
high density areas are marked in red. The invasion front (IF) is pre-
dominantly colored in green. Scale bar 5000 µm
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also found that a loss of EZH2 in ovarian cancer stem cells 
is correlated with growth inhibition. Since cancer stem cells 
are thought to be found at the tumor invasion front, prolifera-
tion stop seems to be a necessary prerequisite for cellular 
plasticity with subsequent changes in cell phenotype that 
enable migration and invasion into the surrounding tissue. 
Additionally, it should be mentioned that EZH2 expression 
was reported to facilitate transformation by blocking line-
age specification (Ezhkova et al. 2009). Interestingly, EZH2 
also represses the enterocyte differentiation program in the 
intestine (Benoit et al. 2012). Moreover, it is suggested that 
EZH2 specifically suppresses transcriptional programs asso-
ciated with alternative phenotypes. Also the finding that a 
complete elimination of EZH2 is impossible in certain tumor 
cell lines due to gene essentiality shows that fate control by 
EZH2 is strongly cell type specific (Grassian et al. 2015). 
Loss of EZH2 and mitotic activity at the invasion front of 
colon cancer seems to play an important role for the acquisi-
tion of mesenchymal characteristics that are required for the 
migration and invasion of disseminating tumor and cancer 
stem cells (Palmqvist et al. 1998, 1999, 2000; Jung et al. 
2001; Jie et al. 2007). This leads to the conclusion that a 
reduction or complete loss of EZH2 expression resulting in a 
stop of proliferation represents a promoting factor associated 
with the dissemination of tumor cells and the formation of 
metastases. Indeed, we found a correlation between EZH2 
and survival of patients only when considering its expres-
sion at the invasion front. In this regard, we detected more 
lymph node and distant metastases, and higher UICC stages 
for patients with a lower EZH2 expression at the invasion 
front. Interestingly the gradient in EZH2 expression reached 
significance in the Multivariate Cox’s analysis suggesting 
that the evaluation of a decrease in EZH2 at invasion front 
is an independent prognostic factor in CRC. This is promis-
ing since the detection of a difference in EZH2 expression 
should be independent of the scoring system used in differ-
ent labs. There was no significant correlation between the 
budding score or the MMRP status and EZH2 expression 
neither in the center nor at the invasion front. In a study 
of Joensuu et al., they found a positive correlation between 
microsatellite unstable tumors and high EZH2 expression 
(Joensuu et al. 2015). Although it is well known that micro-
satellite unstable tumors have a better prognosis, we could 
not confirm this in our tumor group. The reason might be the 
composition of our tumor group that consists of a mixture 
of stage I–IV tumors, and thus the prognostic validity of the 
link between M1 CRC patients with proximal tumors and 
worse prognosis is masked (Merkel et al. 2018).
It is already well accepted that tumors with a more 
aggressive invasion front harm the patients more severely 
and influence their survival. The analysis of different tumor 
areas in the various studies present in the current literature 
could explain their strong discrepancies. It is possible that 
depending on which tumor site is being analyzed, the effect 
of the invasion front is represented in the study results, while 
in other cases more luminal parts are examined and, there-
fore, the characteristics of the invasion front are (largely) 
neglected. As proposed by Wassermann et al. for p16INK4A 
also for EZH2, there might only be a small subpopulation 
of tumor cells that determines the prognosis and that differs 
from the rest of the tumor (Wassermann et al. 2009).
Since CRISPR-Cas ko for EZH2 in HC116 cells was not 
successful (data not shown) in an attempt to mimic EZH2 
status of CRC tumors at the invasion front, we treated 
HCT116 colon tumor cells with a common EZH2 inhibitor 
(DZNep) that is known to decrease the activity and protein 
level of EZH2 (Tan et al. 2007; Sun et al. 2009). We applied 
the in ovo CAM xenograft model to compare the growth 
of control and DZNep-treated HCT116 cells. Remarkably, 
DZNep-treated HCT116 cells formed microtumors showing 
high heterogeneity for EZH2 staining and expression of the 
corresponding H3K27me3 code and a distinct decrease in 
the immunoscores at the tumor invasion front. Moreover, we 
were able to confirm the drug-induced growth arrest caused 
by DZNep treatment for the first time in vivo, since tumors 
formed by DZNep-treated HCT116 cells were only loosely 
packed and showed clearly reduced cell numbers. As antici-
pated in our model system, tumors of DZNep-treated cells 
displayed a more aggressive phenotype. They showed a pro-
nounced invasive behavior with many cell clusters and buds 
infiltrating the CAM. Moreover, a high vessel density could 
be observed. These results underline our findings in patients 
and the fact that EZH2 loss leads to a growth inhibition, 
which represents an important mechanism for disseminat-
ing tumor cells. As already mentioned above, a prolifera-
tion stop at the invasion front of colon cancer has already 
been reported in various other studies (Palmqvist et al. 
1998, 1999, 2000). Moreover, it has been shown that the 
massive upregulation of the cell cycle inhibitor p16(INK4a) 
at the tumor invasion front was strongly associated with a 
decreased Ki67 proliferation index (Jie et al. 2007; Jung 
et al. 2001). In conclusion, our findings give further evi-
dence for EZH2 having a tumor suppressor role in dissemi-
nating tumor cells, which adds a new aspect of bifunctional 
nature to this chromatin-modifying enzyme for determining 
tumor heterogeneity.
Further reasons for the divergent data in the literature 
are the various scoring systems and different cutoff values 
used for the quantification of EZH2 expression that prevent 
a reliable comparison of available studies, even though they 
are all focusing on CRC. For example, Mimori et al. and 
Liu et al. used qRT-PCR, while Fluge et al., Takawa et al., 
and Meng et al. used IHC and Benard et al. combined both 
techniques in their studies, hence applying different quan-
tification criteria and grades of sensitivity for the deter-
mination of EZH2 expression (Benard et al. 2014; Fluge 
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et al. 2009; Liu et al. 2015; Mimori et al. 2005; Takawa 
et al. 2011; Meng et al. 2014). Even within only IHC-based 
studies, the definition of high expression ranged from > 30 
to > 50% EZH2 positive cells or was not clearly specified 
in the reports, while the intensity of a positive staining was 
not considered at all (Takawa et al. 2011). Only Fluge et al. 
applied a staining index that included the intensity with 
values ranging from 1 to 3 (Fluge et al. 2009). Yamamoto 
et al. used a dichotomous expression variable with 40% as 
a cutoff between low- and high-expressing EZH2 tumors 
(Yamamoto et al. 2017). Thus, a reproducible and time 
efficient method for EZH2 scoring could help to stand-
ardize the measurement of EZH2 staining patterns and to 
establish EZH2 as a reliable biomarker in colon cancer. 
So far, except for a single report, the H3K27me3 code has 
not been correlated with EZH2 expression in these studies 
(Benard et al. 2014). We successfully applied our novel 
semi-automated software tool for detection of nuclear 
EZH2 expression. The strong interobserver correlation 
shows that Definiens TSS is a suitable tool for the analy-
sis of big data sets such as TMAs. Since the training of 
the software is very time consuming, especially for inex-
perienced researchers, its use is especially recommended 
for the analysis of big data sets. Applying the software 
can save time and also reduce the risk of errors, especially 
when analyzing TMAs with a high density of punches. 
As the threshold of the intensity cannot be changed in the 
same run, the staining quality should be equal between the 
different specimens; a requirement that is fulfilled today 
using automatic staining procedures. The visualization of 
the results in that heatmaps is an excellent software feature.
In conclusion, we suggest that heterogeneity of EZH2 
expression concerning tumor center and invasion front as 
well as different scoring and cutoff values can most likely 
explain the controversial literature data concerning the 
prognostic value of EZH2. We further propose that, inde-
pendent of the used scoring system, a remarkable loss of 
EZH2 from tumor center to the invasion front could be a 
suitable prognosticator of worse prognosis in daily rou-
tine. Finally, we recommend that epigenetic therapies with 
EZH2 inhibitors should be carefully evaluated for each 
specific tumor type, since alterations in cell differentiation 
might lead to unfavorable results.
Acknowledgements The present work was performed in partial ful-
fillment of the requirements for obtaining the degree “Dr. med.” at 
the FAU Erlangen-Nürnberg for JB. We thank Christa Winkelmann 
for her excellent technical help with immunohistochemical stainings. 
This article is partly based upon work from COST Action CA17118, 
supported by COST (European Cooperation in Science and Technol-
ogy) www.cost.eu.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent This retrospective study is covered by ethic votes of 
the FAU (24.01.2005, 18.01.2012).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
Bachmann IM, Halvorsen OJ, Collett K et al (2006) EZH2 expression 
is associated with high proliferation rate and aggressive tumor 
subgroups in cutaneous melanoma and cancers of the endome-
trium, prostate, and breast. J Clin Oncol 24:268–273. https ://doi.
org/10.1200/JCO.2005.01.5180
Benard A, Goossens-Beumer IJ, van Hoesel AQ et al (2014) Prog-
nostic value of polycomb proteins EZH2, BMI1 and SUZ12 and 
histone modification H3K27me3 in colorectal cancer. PLoS One 
9:e108265. https ://doi.org/10.1371/journ al.pone.01082 65
Benoit YD, Lepage MB, Khalfaoui T et al (2012) Polycomb repressive 
complex 2 impedes intestinal cell terminal differentiation. J Cell 
Sci 125:3454–3463. https ://doi.org/10.1242/jcs.10206 1
Chen JF, Luo X, Xiang LS et al (2016) EZH2 promotes colorectal can-
cer stem-like cell expansion by activating p21cip1-Wnt/β-catenin 
signaling. Oncotarget 7:41540–41558. https ://doi.org/10.18632 /
oncot arget .9236
Crea F, Fornaro L, Bocci G et al (2012) EZH2 inhibition: targeting the 
crossroad of tumor invasion and angiogenesis. Cancer Metastasis 
Rev 31:753–761. https ://doi.org/10.1007/s1055 5-012-9387-3
Ezhkova E, Pasolli HA, Parker JS et  al (2009) Ezh2 orchestrates 
gene expression for the stepwise differentiation of tissue-spe-
cific stem cells. Cell 136:1122–1135. https ://doi.org/10.1016/j.
cell.2008.12.043
Fluge Ø, Gravdal K, Carlsen E et al (2009) Expression of EZH2 
and Ki-67 in colorectal cancer and associations with treatment 
response and prognosis. Br J Cancer 101:1282–1289. https ://doi.
org/10.1038/sj.bjc.66053 33
Fussbroich B, Wagener N, Macher-Goeppinger S et al (2011) EZH2 
depletion blocks the proliferation of colon cancer cells. PLoS One 
6:e21651. https ://doi.org/10.1371/journ al.pone.00216 51
Grassian AR, Scales TME, Knutson SK et  al (2015) A medium-
throughput single cell CRISPR-Cas9 assay to assess gene essen-
tiality. Biol Proc Online 17:15. https ://doi.org/10.1186/s1257 
5-015-0028-4
2239Journal of Cancer Research and Clinical Oncology (2019) 145:2227–2240 
1 3
He SB, Zhou H, Zhou J et al (2014) Inhibition of EZH2 expression 
is associated with the proliferation, apoptosis, and migration of 
SW620 colorectal cancer cells in vitro. Exp Biol Med (Maywood) 
240:458–466. https ://doi.org/10.1177/15353 70214 54221 5
Jie G, Zhixiang S, Lei S, Hesheng L, Xiaojun T (2007) Relationship 
between expression and methylation status of p16INK4a and the 
proliferative activity of different areas’ tumour cells in human 
colorectal cancer. Int J Clin Pract 61:1523–1529. https ://doi.org/
10.1111/j.1742-1241.2006.01033 .x
Joensuu EI, Nieminen TT, Lotsari JE, Pavicic W, Abdel-Rahman WM, 
Peltomäki P (2015) Methyltransferase expression and tumor sup-
pressor gene methylation in sporadic and familial colorectal can-
cer. Genes Chromosomes Cancer 54(12):776–787. https ://doi.
org/10.1002/gcc.22289 
Jung A, Schrauder M, Oswald U et al (2001) The invasion front of 
human colorectal adenocarcinomas shows co-localization of 
nuclear beta-catenin, cyclin D1, and p16INK4A and is a region 
of low proliferation. Am J Pathol 159:1613–1617
Kim KH, Roberts CW (2016) Targeting EZH2 in cancer. Nat Med 
22:128–134. https ://doi.org/10.1038/nm.4036
Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Rein-
berg D (2002) Histone methyltransferase activity associated 
with a human multiprotein complex containing the enhancer of 
zeste protein. Genes Dev 16:2893–2905. https ://doi.org/10.1101/
gad.10359 02
Liu YL, Gao X, Jiang Y et al (2015) Expression and clinicopatho-
logical significance of EED, SUZ12 and EZH2 mRNA in colo-
rectal cancer. J Cancer Res Clin Oncol 141:661–669. https ://doi.
org/10.1007/s0043 2-014-1854-5
Lugli A, Kirsch R, Ajioka Y et  al (2017) Recommendations for 
reporting tumor budding in colorectal cancer based on the Inter-
national Tumor Budding Consensus Conference (ITBCC) 2016. 
Mod Pathol 30(9):1299–1311. https ://doi.org/10.1038/modpa 
thol.2017.46
Margueron R, Reinberg D (2011) The Polycomb complex PRC2 and 
its mark in life. Nature 469:343–349. https ://doi.org/10.1038/natur 
e0978 4
Meng X, Huang Z, Wang R et  al (2014) The prognostic role of 
EZH2 expression in rectal cancer patients treated with neoad-
juvant chemoradiotherapy. Radiat Oncol 9:188. https ://doi.
org/10.1186/1748-717X-9-188
Merkel S, Schellerer VS, Wein A et al (2018) The influence of tumour 
site on prognosis in metastatic colorectal carcinomas with primary 
tumour resection. Int J Colorectal Dis. https ://doi.org/10.1007/
s0038 4-018-3098-3
Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M (2005) 
Clinical significance of enhancer of zeste homolog 2 expression 
in colorectal cancer cases. Eur J Surg Oncol 31:376–380. https ://
doi.org/10.1016/j.ejso.2004.11.001
Muenzner JK, Kunze P, Lindner P (2018) Generation and characteri-
zation of hepatocellular carcinoma cell lines with enhanced can-
cer stem cell potential. J Cell Mol Med. https ://doi.org/10.1111/
jcmm.13911 
Nolte S, Zlobec I, Lugli A et al (2017) Construction and analysis of 
tissue microarrays in the era of digital pathology: a pilot study tar-
geting CDX1 and CDX2 in a colon cancer cohort of 612 patients. 
J Pathol Clin Res 3:58–70. https ://doi.org/10.1002/cjp2.62
Palmqvist R, Oberg A, Bergström C, Rutegård JN, Zackrisson B, 
Stenling R (1998) Systematic heterogeneity and prognostic 
significance of cell proliferation in colorectal cancer. Br J Cancer 
77:917–925
Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegård JN, Stenling 
R (1999) Low tumour cell proliferation at the invasive margin 
is associated with a poor prognosis in Dukes’ stage B colorec-
tal cancers. Br J Cancer 79:577–581. https ://doi.org/10.1038/
sj.bjc.66900 91
Palmqvist R, Rutegârd JN, Bozoky B, Landberg G, Stenling R (2000) 
Human colorectal cancers with an intact p16/cyclin D1/pRb path-
way have up-regulated p16 expression and decreased proliferation 
in small invasive tumor clusters. Am J Pathol 157:1947–1953. 
https ://doi.org/10.1016/S0002 -9440(10)64833 -X
Ribatti D (2017) The chick embryo chorioallantoic membrane (CAM) 
assay. Reprod Toxicol 70:97–101. https ://doi.org/10.1016/j.repro 
tox.2016.11.004
Sha M, Mao G, Wang G, Chen Y, Wu X, Wang Z (2015) DZNep inhib-
its the proliferation of colon cancer HCT116 cells by inducing 
senescence and apoptosis. Acta Pharm Sin B 5:188–193. https ://
doi.org/10.1016/j.apsb.2015.01.011
Simon JA, Lange CA (2008) Roles of the EZH2 histone methyl-
transferase in cancer epigenetics. Mutat Res 647:9. https ://doi.
org/10.1016/j.mrfmm m.2008.07.010
Sun F, Chan E, Wu Z, Yang X, Marguez VE, Yu Q (2009) Combi-
natorial pharmacologic approaches target EZH2-mediated gene 
repression in breast cancer cells. Mol Cancer Ther 8:3191–3202. 
https ://doi.org/10.1158/1535-7163.MCT-09-0479
Takawa M, Masuda K, Kunizaki M et al (2011) Validation of the his-
tone methyltransferase EZH2 as a therapeutic target for various 
types of human cancer and as a prognostic marker. Cancer Sci 
102:1298–1305. https ://doi.org/10.1111/j.1349-7006.2011.01958 
.x
Tamagawa H, Oshima T, Numata M et al (2013) Global histone modi-
fication of H3K27 correlates with the outcomes in patients with 
metachronous liver metastasis of colorectal cancer. Eur J Surg 
Oncol 39:655–661. https ://doi.org/10.1016/j.ejso.2013.02.023
Tan J, Yang X, Zhuang L et al (2007) Pharmacologic disruption of 
Polycomb-repressive complex 2-mediated gene repression selec-
tively induces apoptosis in cancer cells. Genes Dev 21:1050–
1063. https ://doi.org/10.1101/gad.15241 07
Vilorio-Marqués L, Martín V, Diez-Tascón C et al (2017) The role of 
EZH2 in overall survival of colorectal cancer: a meta-analysis. 
Sci Rep 7:13806. https ://doi.org/10.1038/s4159 8-017-13670 -z
Wassermann S, Scheel SK, Hiendlmeyer E et al (2009) p16INK4a is 
a beta-catenin target gene and indicates low survival in human 
colorectal tumors. Gastroenterology 136:196–205. https ://doi.
org/10.1053/j.gastr o.2008.09.019
Wei Y, Xia W, Zhang Z et al (2008) Loss of trimethylation at lysine 27 
of histone H3 is a predictor of poor outcome in breast, ovarian, 
and pancreatic cancers. Mol Carcinog 47:701–706. https ://doi.
org/10.1002/mc.20413 
Yamamoto I, Nosho K, Kanno S et al (2017) EZH2 expression is a 
prognostic biomarker in patients with colorectal cancer treated 
with anti-EGFR therapeutics. Oncotarget 8:17810–17818. https 
://doi.org/10.18632 /oncot arget .14863 
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
2240 Journal of Cancer Research and Clinical Oncology (2019) 145:2227–2240
1 3
Affiliations
Julian Böhm1,2 · Julienne Kathrin Muenzner1,2 · Aylin Caliskan1,2 · Benardina Ndreshkjana1,2 · 
Katharina Erlenbach‑Wünsch2 · Susanne Merkel3 · Roland Croner3,4 · Tilman T. Rau2,5 · Carol Immanuel Geppert2 · 
Arndt Hartmann2 · Adriana Vial Roehe6 · Regine Schneider‑Stock1,2 
 Julian Böhm 
 julian.boehm@uk-erlangen.de
 Julienne Kathrin Muenzner 
 julienne.muenzner@uk-erlangen.de
 Aylin Caliskan 
 aylin.caliskan@gmx.de
 Benardina Ndreshkjana 
 benardina.ndreshkjana@uk-erlangen.de
 Katharina Erlenbach-Wünsch 
 katharina.erlenbach-wuensch@uk-erlangen.de
 Susanne Merkel 
 susanne.merkel@uk-erlangen.de
 Roland Croner 
 roland.croner@med.ovgu.de
 Tilman T. Rau 
 tilman.rau@pathology.unibe.ch
 Carol Immanuel Geppert 
 carol.geppert@uk-erlangen.de
 Arndt Hartmann 
 arndt.hartmann@uk-erlangen.de
 Adriana Vial Roehe 
 adrianar@ufcspa.edu.br
1 Experimental Tumorpathology, Institute of Pathology, 
Friedrich-Alexander-University of Erlangen-Nürnberg, 
Universitätsstr. 22, 91054 Erlangen, Germany
2 Institute of Pathology, Friedrich-Alexander-University 
of Erlangen-Nürnberg, Krankenhausstr. 8-10, 
91054 Erlangen, Germany
3 Department of Surgery, Friedrich-Alexander-University 
of Erlangen-Nürnberg, Krankenhausstr. 12, 91054 Erlangen, 
Germany
4 Department of Surgery, Otto-von-Guericke University, 
Leipziger Str. 44, 39120 Magdeburg, Germany
5 Institute of Pathology, University Bern, Murtenstr. 31, 
3008 Bern, Switzerland
6 Department of Pathology, Federal University of Health 
Sciences of Porto Alegre (UFCSPA), R. Sarmento Leite, 
245-Centro Histórico, Porto Alegre, RS 90050-170, Brazil
